Malaria is a preventable and treatable parasitic disease, but diagnosing it can be a challenge in the developing countries where it’s most prevalent. Malaria is caused by the Plasmodium parasite, which has a complex life cycle involving both a vector, usually the female Anopheles mosquito, and the human host. The parasite enters the host blood stream through the saliva of an infected mosquito as they bite. After Plasmodium enters the blood stream it can lay dormant for long periods of time (months) before causing symptoms like cramps, chills, and fever.
Many patients do not reach clinics until after malaria symptoms are present, and early cases are often sent home due to current malaria diagnosis methods being less effective at early stages of the disease. Mosquitoes can still bite and then transmit malaria from asymptomatic hosts; making early diagnosis an important step in the elimination and eventual eradication of the malaria.
As part of the Global Good program, scientists and engineers at IV Lab continue to work on developing new malaria diagnostic technology in support of elimination and eventual eradication of malaria.
We’re thrilled to announce Global Good’s recent partnership with GE Ventures and the Global Research Center. Yesterday’s GE Report profiles the work Global Good, GE Ventures, and the GE Global Research Center will pursue on an affordable test platform that can be deployed anywhere and detect hidden cases of malaria that the conventional tests do not catch.
Learn more about Global Good’s new partnership, here.